Current Report Filing (8-k)
February 16 2022 - 3:02PM
Edgar (US Regulatory)
0001081938
false
0001081938
2022-02-14
2022-02-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
U.S. SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
Current Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 14, 2022
Cannapharmarx, Inc.
(Exact name of small business issuer as specified
in its charter)
Delaware |
333-251016 |
27-4635140 |
(State or other jurisdiction of incorporation)
|
(Commission File Number) |
(IRS Employer ID No.) |
Suite
3600
888-3rd Street SW
Calgary, Alberta, Canada T2P5C5
(Address of principal executive offices)
(949) 652-6838
(Issuer’s Telephone Number)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b)
of the Act:
None
Securities registered pursuant to Section 12(g)
of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock |
CPMD |
OTC Pink Sheets |
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule
12b2 of the Securities Exchange Act of 1934 (§240.12b2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 7.01 | Regulation FD Disclosure |
Attached is a copy of a press release being issued by the Company relating
to the Letter of Intent, a copy of which is attached as Exhibit 99.6 and is hereby incorporated.
| Item 9.01. | Financial Statements and Exhibits. |
(c) Exhibits.
Number |
Exhibit |
99.6 |
Press Release |
104 |
Cover Page Interactive Data File formatted in inline XBRL |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned, hereunto duly
authorized.
|
CANNAPHARMARX, INC. |
|
|
|
By: |
/s/ Dominic Colvin |
|
|
Dominic Colvin Chief Executive Officer |
Cannapharmarx (PK) (USOTC:CPMD)
Historical Stock Chart
From May 2024 to Jun 2024
Cannapharmarx (PK) (USOTC:CPMD)
Historical Stock Chart
From Jun 2023 to Jun 2024